Ionis surged after FDA approval of Dawnzera, the first RNA-targeted prophylactic for hereditary angioedema. BofA raised its target to $64 (Buy), while Stifel lifted to $43 (Hold), citing the drug's clean label and flexible dosing. Phase 3 data showed an 81% drop in attacks, with longer-term reductions above 90%. Retail sentiment on Stocktwits turned 'extremely bullish.'